Company News 03 Feb 2025 Orthocell Submits Canada Regulatory Application to Commence Sales of Remplirâ„¢ into US$75million Canadian market Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its… Orthocell
Company News 22 Jan 2025 Orthocell Accelerates Global Expansion: Five New Country Regulatory Submissions Planned in 2025 On the back of outstanding early sales traction for Remplirâ„¢ in Australia, New Zealand and Singapore, Orthocell has announced that… Orthocell
Company News 20 Jan 2025 Orthocell receives $3.18m R&D tax incentive refund Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year. Orthocell
Company News 08 Jan 2025 OCC Quarterly Report | Quarter ended 31 December 2024 Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter. Orthocell
Company News 19 Dec 2024 Orthocell Submits U.S. FDA Regulatory Application Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplirâ„¢ into the… Orthocell
Company News 12 Dec 2024 Orthocell Achieves Major Milestone with First Sales of Remplirâ„¢ in Singapore Orthocell has today announced the achievement of first sales of Remplirâ„¢ in Singapore, marking another significant milestone in its global… Orthocell
Company News 02 Dec 2024 Orthocell successfully completes US FDA 510(k) regulatory study for Remplirâ„¢ Orthocell has today reached another significant milestone with the successful completion of its Remplirâ„¢ 510(k) nerve repair regulatory study, validating… Orthocell
Company News 27 Nov 2024 Orthocell Appoints Exclusive Distributor to Commence Sales of Remplirâ„¢ in Singapore Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair… Orthocell
Company News 11 Nov 2024 Appointment of Key US Executives to Lead Remplirâ„¢ Launch Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplirâ„¢ following the expected US… Orthocell
Company News 08 Oct 2024 Orthocell Receives Regulatory Approval for Remplirâ„¢ in Singapore Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of… Orthocell
